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ABSTRACT
Technology in hemostasis laboratories has evolved enormously during the last
30 years. Although many scientists and clinicians will remember the traditional tilt-tube
techniques to screen for coagulation abnormalities and to monitor anticoagulant therapy,
the hemostasis laboratory today uses a variety of modern technologies. These include flow
cytometry, chromogenic assays, molecular typing (e.g., polymerase chain reaction), im-
munologic assays (e.g., enzyme-linked immunosorbent assays), functional assays of specific
coagulation proteins, and platelet function analyzers. Although these advances in tech-
nology have resulted in greater capability, productivity, sensitivity, specificity, and ulti-
mately, improvement in the clinical care of patients, controversies and limitations remain.
This article highlights new and emerging technologies in hemostasis and discusses whether
they have improved or are likely to improve laboratory diagnostics by specifically addressing
the following: (1) Can new technologies help predict likelihood of thrombosis recurrence?
(2) Has an understanding of the role of a disintegrin-like and metalloprotease with
thrombospondin type 1 motifs (ADAMTS13) in microangiopathy resulted in improved
diagnostic methods for this disorder? (3) Does thrombelastography allow better definition
of bleeding risk than conventional hemostasis assays, especially in settings of acute
hemostatic pathology?
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CAN NEW TECHNOLOGIES HELP PREDICT
LIKELIHOOD OF THROMBOSIS
RECURRENCE?
Conventional thrombophilia testing has helped to ex-
plain thrombophilic mechanisms, but has been less help-
ful in defining ongoing thrombotic risk. Despite the
effectiveness of current anticoagulation therapy, defining
the optimal duration of therapy remains a problem for
clinicians and patients alike. Given the bleeding risk of
vitamin K antagonists (VKAs) such as warfarin, indef-
inite anticoagulation should be restricted to patients
with a high risk of recurrent venous thromboembolism
(VTE). Follow-up of a large patient cohort after a first
symptomatic deep vein thrombosis (DVT) demon-
strated that more than 20% will suffer a recurrent event
within 5 years.1 However, our inability to define which
patients are in the 20 to 30% at high risk exposes the
whole cohort to risk of complications from continued
therapy with VKA. Clinical parameters, such as an
idiopathic thrombosis, past history of VTE, or even
being a male, are markers of increased risk of recurrence,
but none of these factors alone are indications for
indefinite warfarin. There is a clear need for a laboratory
assay of hypercoagulability that predicts recurrent
thrombosis.
Thrombophilia Screening
The ability of conventional thrombophilic factors to
predict recurrence remains controversial. Earlier stud-
ies reported higher rates of recurrent VTE in the
presence of antiphospholipid antibodies2,3 and elevated
levels of factor (F) VIII:coagulant activity (C).4,5
However, the high prevalence of these abnormalities
in the normal population and uncertainty about labo-
ratory criteria for identifying abnormal results have
hampered the clinical application of these tests. In
reviewed retrospective case-control studies,6 heterozy-
gous carriage of either the FV Leiden or prothrombin
20210A mutations was not a significant risk factor for
recurrence, but compound heterozygotes had higher
hazard ratios (HRs) of 2.4 to 4.8. Several recent
prospective studies have addressed this question.
One or more thrombophilic markers (deficiencies of
antithrombin, protein C and S, acquired protein C
resistance, FV R506Q and PT20210A mutations,
hyperhomocysteinemia, and antiphospholipid antibod-
ies) were found in 30% of 195 patients with a first
episode of idiopathic proximal DVT and treated for
either 3 or 12 months.7 After 46 months follow-up,
recurrence rates were higher in the thrombophilic
cohort (35.1%) than in those with normal test results
(21%; p¼ 0.046). However, the excess of recurrent
events was only seen in patients who received 3 months
of anticoagulation; recurrence rates were similar in
both the thrombophilic and normal cohorts after
12 months of treatment. The risks of stopping warfarin
in patients with familial thrombophilia was addressed
in 180 patients with either factor V Leiden or defi-
ciencies of antithrombin, protein C, or protein S who
did not receive long-term anticoagulation after a first
event.8 Recurrent VTE occurred at a rate of 5%/year
(during a mean 5.6-year follow-up) in this cohort,
compared with a rate of 1%/year in those remaining
on anticoagulation. Although this study found a higher
risk in males compared with females, the recurrence
rates seen here may not be high enough to justify
indefinite anticoagulation in all patients with a throm-
bophilic defect. Therefore, testing for individual
thrombophilic factors, with the possible exception of
antiphospholipid antibodies, is unlikely to determine
the duration of anticoagulation.
D-Dimer
At present, the most promising assay for the prediction
of recurrence is an old assay revisited. Plasma levels of D-
dimer have not been demonstrated to be specific for
DVT and pulmonary embolism, but are a sensitive
marker of fibrin formation, and thus a potential indicator
of the activity of the coagulation pathways. In a small
prospective study of D-dimer levels during warfarin
therapy, elevated levels at diagnosis normalized within
6 weeks in 13 patients with nonidiopathic DVT, whereas
five of nine patients with idiopathic DVT showed
persisting elevation.9 Recent studies have suggested
that elevated D-dimer levels, typically measured after
the cessation of warfarin therapy, may be a marker for
recurrent thrombosis10,11; however, a subsequent study12
reported that thrombophilic carriers with normal
D-dimer levels had a very low risk of recurrence, sug-
gesting that a negative result may be a more useful
predictor. The D-dimer assay used in this study
(VIDASD-Dimer enzyme-linked immunosorbent assay
[ELISA]; bioMe`rieux; Marcy l’Etoile, France) had a
sensitivity of 62% and specificity of 65.6% across all
subjects, but a negative predictive value of 94%.12 Given
that only 16% of patients with elevated D-dimer suffered
a recurrence, its positive predictive value appears limited.
The contribution of D-dimers was also com-
pared with residual venous obstruction (RVO) in a
prospective cohort study of 400 patients with idio-
pathic proximal DVT.13 In this study, elevated D-
dimer level was an independent risk factor for recur-
rence at 2 years (HR, 3.32; 95% confidence interval,
1.78 to 6.75), whereas RVO at the time of warfarin
cessation did not contribute significantly. Of the pa-
tients with high D-dimer levels, 25.9% had recurrent
thromboembolic events, compared with 5.7% and
10.4% for those with normal D-dimer levels and the
absence of presence of RVO, respectively. Taken
together, these studies provide good evidence that
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D-dimer levels, measured after cessation of warfarin,
can identify a group at low risk of recurrence. This
hypothesis is being tested in a management study
(PROLONG), in which elevated D-dimer levels after
cessation become an indication to recommence war-
farin. From the viewpoint of both the clinician and
patient, it would be preferable to identify a high-risk
cohort without stopping warfarin; whether D-dimer
assays can be used for this purpose remains to be
proven.
Thrombin Generation
Thrombin plays a central role in coagulation, modu-
lating both pro- and antithrombotic pathways. Our
conventional clotting times are poor markers of throm-
bin activity, given that 95% of thrombin generation
occurs after the generation of fibrin. Thrombin gen-
eration assays have evolved considerably since the
1950s, as reviewed recently.14 Crucial advances include
the use of a slow-reacting, fluorogenic substrate, al-
lowing one-stage measurement in the presence of
fibrin, and calibration against a nonclotting control.
Among several competing systems, the most widely
studied have been the endogenous thrombin potential
(ETP)15 and a commercial system, calibrated auto-
mated thrombography (CT), which can also measure
thrombin generation in platelet-rich plasma.16,17 Mul-
tiple groups are now using the CT or thrombogram to
screen different patient groups, and it has been recog-
nized that the CT analysis can be performed on fresh
and frozen-thawed PRP, but results are dependent on
tissue factor and phospholipid concentrations.18 Fur-
ther modifications, such as collection into corn trypsin
inhibitor, have been proposed to prevent in vitro
thrombin generation via the contact factor pathway.18
Although the sensitivity of these assays to thrombo-
philic conditions has been studied in small groups of
patients,15,19–21 the recent availability of a standardized
assay should enable researchers to study larger patient
groups, and define the temporal relationships between
thrombin potential, thrombotic events, and subsequent
therapy.
The large Austrian Study on Recurrent Venous
Thromboembolism22 recently has confirmed an asso-
ciation between thrombin generation and VTE recur-
rence. Plasma samples were collected from 914
patients at a median of 13 months after ceasing anti-
coagulation for a first spontaneous VTE. It is impor-
tant to note that this study excluded those with
deficiencies of antithrombin III, protein C, protein
S, lupus anticoagulants, cancer, or pregnancy. Peak
thrombin was higher in women than in men, and in
those with the prothrombin 20210G mutation, but not
in carriers of FV Leiden. By tertiles of peak thrombin,
the risk of recurrence increased, so that the highest
tertile (> 400 nM) had a 20% risk at 4 years compared
with 6.5% for the remaining two thirds (p < 0.001).
Mean peak thrombin levels were higher in those with
recurrence (420 nM) than in those without (349 nM),
but the assay levels were similar for spontaneous and
precipitated recurrent events. The authors propose that
the threshold of 400 nM can be used to identify a
group at low risk of recurrence, for whom long-term
warfarin is not appropriate. This is consistent with the
D-dimer studies, but the low-risk group here com-
prises a larger proportion. Comparative studies are
needed, using the widely used thrombin generation
methods (ETP/CT) to determine if these are also
predictive. Finally, there is now the potential to study
the contribution of platelets to thrombin generation in
these patients.
Other Novel Assays For Predicting Risk of
Thrombosis
Other global assays of coagulation are under develop-
ment that could identify high- or low-risk cohorts
among VTE patients. These have been reviewed re-
cently,14 and include indirect measures of thrombin
measurement, such as thromboelastography (also dis-
cussed later in this review) and studies of fibrin polymer-
ization. The overall hemostatic potential (OHP)
developed by He et al23 quantitates fibrin generation
and lysis in vitro, in response to trace amounts of
thrombin/tissue factor and tissue plasminogen activator.
Hypercoagulable OHP patterns may persist long after a
thrombotic event24 and also were observed in a subset of
patients receiving therapeutic doses of warfarin.25 As
with the D-dimer assays, testing of patients for recur-
rence risk ideally would be done before stopping war-
farin. Additional modifications of the OHP assay may
increase its sensitivity for thrombophilic defects.19 The
role procoagulant phospholipid plays in clotting can also
be assessed by a simple and easily automated technique
that measures the ability of plasma, platelet-rich plasma,
or whole blood to enhance the activity of activated FX.26
This may prove to be a useful and rapid screening test for
hypercoagulable patients.
There is growing consensus that the so-called
reductionist approach to VTE (testing for an ever-
increasing number of thrombophilic factors) is of
limited utility in predicting recurrence risk.14 The
reductionist approach is also associated with a greater
chance of generating false-positive results.27 Instead, it
is hoped that global coagulation assays, which inte-
grate multiple inherited, acquired, and temporary in-
fluences, will be more useful. Thrombin-generation
assays are reproducible enough for clinical studies,
and one system at least has shown a similar low
recurrence risk in patients with low/normal levels of
peak thrombin.6 The sensitivity of many of these
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assays to known thrombotic risk factors is not well
defined. Patients with natural anticoagulant deficien-
cies and antiphospholipid antibodies often have been
excluded from studies on the premise that they require
indefinite warfarin after a first event. However, as a
recent review noted,14 to be clinically useful, global
assays of coagulation must do more than just detect the
inherited thrombophilias. Until we have a greater
range of treatment options, a first priority is to identify
low-risk patients and limit their exposure to antico-
agulation.
HAS AN UNDERSTANDING OF THE ROLE
OF ADAMTS13 IN MICROANGIOPATHY
IMPROVED DIAGNOSTIC METHODS FOR
THIS DISORDER?
Mortality from thrombotic thrombocytopenic purpura
(TTP) has declined substantially since early interven-
tion with plasma exchange has become routine therapy.
In addition, the pathophysiology of many cases of acute
and chronic relapsing TTP has been defined following
the recognition of the cleaving protease ADAMTS13
(a disintegrin-like and metalloprotease with thrombo-
spondin type 1 motifs). Mortality from TTP was
common until the 1970s, when it was discovered
experimentally that treatment by plasmapheresis com-
bined with replacement fresh frozen plasma was often
an effective means of overcoming the acute phase.28
Early diagnosis and rapid initiation of this treatment
has resulted in a dramatic improvement in survival of
greater than 80%,29 highlighting the need for clear
diagnostic criteria.
In 1996, two groups independently isolated a
protease that cleaved von Willebrand factor (vWF)
multimers.30,31 This protein was later shown to be
absent in congenital TTP32 as well as autoantibody-
induced, acquired TTP.33 The enzyme, then known as
von Willebrand factor cleavage protease, was subse-
quently sequenced and identified as a metalloprotease
and designated ADAMTS13.34 The discovery that
ADAMTS13 deficiency was the cause of most cases of
TTP led to an understanding of the probable patho-
physiology. It had been known for some time that very
large multimers of vWF were present in the plasma of
many patients with TTP,35 and a series of in vitro
experiments, using both recombinant and human-derived
ADAMTS13, demonstrated that vWF multimers are
cleaved by this enzyme, probably under conditions of
high shear stress. It is likely that deficiency of
ADAMTS13 leads to accumulation of highly procoagu-
lant ultra large multimers of vWF in vivo with resultant
thrombus formation in the microvasculature.36,37 In cases
of microangiopathic hemolytic anemia where TTP seems
likely, the laboratory now has several options to help
establish the diagnosis. These are the demonstration of
very high multimers of vWF, a reduction in the func-
tional or antigenic levels of ADAMTS13, or the presence
of antibodies to the enzyme.
vWF Multimer Assays
Multimeric patterns of vWF traditionally have been used
to help categorize the clinical types of von Willebrand
disorder. Multimers are separated by electrophoresis
through a low-concentration agarose gel, followed by
immunoblotting. The bands can be visualized by either
radioactive38 or enzyme-linked antibody to vWF.39 The
assay is complex and time consuming and therefore
usually is only performed in specialized centers, with
results rarely available quickly enough to be of value in
reaching a diagnosis of TTP.
ADAMTS13 Functional Assays
These were reviewed in detail by Veyradier and Girma in
2004.40 At that time the available techniques were
technically demanding, and were based on electropho-
resis,30,31,41–43 measurement of residual vWF anti-
gen,44,45 or measurement of residual vWF activity46–49
after incubation of vWF with test plasma. Since then,
there have been several major improvements, including
an automated activity assay49 that can be completed
within a few hours,50 a technique using the Impact-R
(DiaMed, Cresier, Switzerland) cone and plate analyzer
to measure the effect of TTP plasma on the adherence of
normal platelets to a polystyrene well under conditions of
high shear stress,51 and a fluorescent resonance energy
transfer assay for ADAMTS13 activity that can be
completed within 2 hours.52
ADAMTS13 Antigen Assays
Following an initial abstract reporting an ELISA in
2004,53 the last 12 months have seen a major break-
through in laboratory testing for ADAMTS13 and its
antibodies. A technique, published in January 2006,
used a peptide containing the ADAMTS13 cleavage
site linked to a horseradish peroxidase. The method is
rapid, sensitive, and reproducible.54 Rieger et al55
reported a sandwich ELISA using polyclonal rabbit
anti-ADAMTS13 as the capture antibody and perox-
idase-complexed rabbit antihuman immunoglobulin
(Ig) G as the detection antibody. This method was
sensitive to low levels of ADAMTS13. In cases of
inherited TTP, the authors demonstrated that circulat-
ing ADAMTS13 antigen/antibody complexes could be
detected by the antibodies, producing normal antigenic
levels and rendering the assay of limited value in such
cases. The latest reported technique used a monoclonal
ADAMTS13 as the capture antibody with two bio-
tinylated anti-ADAMTS13 antibodies for detection.56
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With this method, all 11 patients with acquired TTP
had low ADAMTS13 levels. There are now commer-
cially available ELISA kits from American Diagnostica
(Stamford, CT) and Technoclone (Vienna, Austria).
ADAMTS13 Antibody Assays
Treatment of acquired TTP differs from treatment
of congenital TTP in that plasma exchange and immu-
nosuppression are needed in the former, whereas epi-
sodes of the familial form often can be managed
successfully by fresh frozen plasma infusion. Demon-
stration of a circulating antibody is therefore clinically
useful. Most of the assays described here have been
adapted for the detection of antibody in cases of acquired
TTP. Prior to assay, a mixture of test and normal plasma
is incubated and the residual ADAMTS13 in the normal
plasma is estimated using electrophoresis,33 the colla-
gen-binding technique,45 estimation of vWF:ristocetin
cofactor activity by aggregometry,47,48 or vWF:antigen
by immunoradiometric analysis.45 Park et al57 purified
patient IgG by affinity chromatography on protein A
Sepharose prior to incubation with normal plasma and
assessment of residual activity using the technique of
Furlan et al.33 ELISA techniques are also suitable for
detection of antibody. In the first technique described,
Scheiflinger et al58 detected nonneutralizing antibodies
not detected by a more traditional electrophoretic
method. The more recent techniques of Wu et al54
and Rieger55 are also suitable for antibody detection
and antibody kits are now commercially available.
Methods for the quantitation of ADAMTS13
have improved enormously in simplicity and precision
since the enzyme was first described 10 years ago. It is
now within the scope of most medium to large diag-
nostic laboratories to run these tests. In cases of con-
genital or acquired TTP, low ADAMTS13 levels or the
detection of circulating antibodies are powerful diagnos-
tic indicators. However, problems remain. Not all cases
of clinically diagnosed idiopathic TTP have low
ADAMTS13 levels.59 Normal levels can also be found
in acquired TTP by ELISA, when circulating immune
complexes that cause the clinical syndrome block the
activity of the protease but do not cause its removal from
the circulation.55 In these cases simultaneous measure-
ment of antibody levels is important. Whether severe
ADAMTS13 deficiency is a specific marker for TTP
remains controversial60,61; it had been suggested that
ADAMTS13 may also be reduced in other clinical
conditions.62,63
Nonetheless, it is likely that these issues will be
resolved rapidly. The disorder is rare and to date there
has only been limited availability of ADAMTS13 assays.
Indeed it is likely that the classification of thrombotic
microangiopathies will be refined on the basis of studies
during the next few years.34,59 The newer techniques
should also facilitate population studies, allow genetic
counseling, optimize therapy, and help identify those at
risk of recurrence.
DOES THROMBOELASTOGRAPHY ALLOW
BETTER DEFINITION OF BLEEDING RISK
IN ACUTE HEMOSTATIC SETTINGS THAN
CONVENTIONAL TESTS?
Conventional hemostasis assays define bleeding risk, but
have limitations in settings of acute hemostatic pathol-
ogy. Acute bleeding in patients is a complex medical
emergency, often complicated by the multifactorial na-
ture of the bleeding. More than in any other patient, the
coexistence of associated pathologies, such as sepsis, liver
and/or renal failure, cardiac insufficiency, and the effects
of multiple drugs can affect the hemostatic balance. The
coagulopathy can often be very complex and the hemo-
static balance can change rapidly due to the effects of the
consumption of clotting factors, hyperfibrinolysis, de-
fects of fibrin polymerization, hypothermia, hyper- or
hypokalemia, or hypocalcemia secondary to citrate effect
with calcium and magnesium chelation.64,65
The capacity to differentiate between surgical or
hemostatic causes of bleeding is essential. Transfusion
therapy is often given based on certain thresholds
(hemoglobin, hematocrit, platelet count) and algo-
rithms based on number and type of products infused.
Inappropriate blood replacement can cause severe coa-
gulopathies by further diluting depleted clotting fac-
tors. Abnormalities of laboratory tests are not specific
and can be found also in nonbleeding patients. In
addition, turnaround time of traditional hemostasis
tests (prothrombin time, activated partial thromboplas-
tin time, fibrinogen, thrombin time, and platelet count)
results in reduced usefulness of the test because most
often the patient has moved to a different hemostatic
balance from the time the sample was taken. This
means that traditional clotting tests will give us infor-
mation only about the past and never about the present.
Therapeutic decisions must be made in real time or as
close to real time as possible.
The type of information gained from these tests is
also limited because none of the current tests gives
insight into the fibrinolytic component of the hemostatic
balance, the quality of the platelet function, the presence
of fibrin polymerization disorders, the presence of sub-
stances interfering with fibrin formation, mild fibrino-
gen deficiencies, or FXIII activity. It is well known that
these tests correlate poorly with a bleeding tendency or
propensity. Furthermore, testing on plasma reveals little
about the cellular interactions in the hemostatic system
that we now understand are complex and drive the final
event of clot formation. More specialized testing of
hemostasis also has limitations, including platelet ag-
gregometry (which is technically challenging and time
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consuming) and platelet function analyzers (which pro-
vide a measure of primary hemostasis exclusively).
Clearly there is a need for more predictive tests in
the acutely bleeding patient. The ideal in vitro test needs
to recognize in vivo interactions between the classic
elements involved in hemostasis, including the endothe-
lium, platelets, and clotting factors, as well as other less
recognized elements, including other cells (e.g., mono-
cytes, cancer cells), metabolic effects from pathological
states (e.g., uremia and paraproteinemia), medications,
and fibrinolytic potential. Thrombin burst is also im-
portant, hence the intense interest in a global test of
thrombin generation. Several commercial tests have been
developed or are being evaluated (see previous discussion
on thrombin generation assays), including thromboelas-
tography (TEG).
Thromboelastography
TEG is a global assay in which the interaction of
coagulation factors, platelets, fibrinolytic factors, in-
hibitors, drugs, and several other factors is assessed via
the continuous registration of the stability of the
forming blood clot under low shear conditions that
mimic the flow conditions of venous blood. It provides
a kinetic analysis of the entire clot formation and
stabilization as well as clot dissolution by the fibrino-
lytic system. Quite distinct from traditional clotting
tests, it is capable of providing information on some of
the critical aspects of the clot formation process. The
different parameters measured are dependent on the
rate of formation, strength, elasticity, and firmness of
the forming clot.66,67
The use of whole blood allows ex vivo investiga-
tion of the clotting process and its interactions with
cellular components such as leukocytes and erythrocytes.
Furthermore, TEG is influenced by the interaction of
platelets with coagulation proteins, including initial
contact with thrombin, platelet aggregation, cross-link-
ing of fibrin, and clot stabilization. This technology also
measures clot dissolution and hence generates quantita-
tive and qualitative information on fibrinolytic activity.
No other routine clotting test currently is capable of
providing all of this information.68 TEG can be used as a
point-of-care test, such as in the operating theater where
continuous monitoring of the hemostatic balance com-
bined with a transfusion algorithm can lead to more
appropriate use of blood products, resulting in significant
savings.69
Although TEG provides a global overview and
selective information about the main pathways in hemo-
stasis, there are limitations associated with this technol-
ogy. Although it is sensitive to a deficiency or excess of
coagulation factors, specific clotting factor deficiencies
cannot be identified. In addition, TEG does not reflect
coagulation associated with endothelial cells and is
sensitive only to severe, rather than mild forms of
fibrinolysis. Currently, it is not standardized between
laboratories due to the diversity in equipment, software,
and variations in methodology,70 has a relatively long
measurement time, and requires technical expertise.
TEG has been explored extensively in surgery71,72
and trauma.73–76 It has also demonstrated promising
results as a valuable test to monitor responses to admin-
istration of activated FVII for the treatment of patients
with hemophilia and inhibitors in the setting of life-
threatening acute bleeding.77–79 Several authors have
investigated the use of TEG as part of an algorithm to
guide blood product replacement during surgery. The
bulk of the published evidence relates to studies per-
formed during cardiopulmonary bypass surgery. Despite
the limitation that in most cases the size of the patient
population analyzed is small, the overall conclusion was
that TEG was useful in significantly reducing (three- to
eight-fold) the use of blood products, particularly plate-
lets and fresh frozen plasma, in the postoperative period.
The reduction in use of blood products was achieved
despite no differences or changes in intraoperative blood
loss between patients monitored with TEG and the
patients managed with standard transfusion therapy
and laboratory tests.80–82 Other possible applications of
TEG include identification of patients at higher risk of
bleeding during and after cardiac surgery,83,84 monitor-
ing the potential of FXIII administration to increase clot
firmness,85 and identification of hypercoagulability fol-
lowing acute bleeding and massive transfusions. The
future utility of TEG in diagnostic and clinical settings
will be dependent on method standardization and soft-
ware developments to allow for improved raw data
analysis, and application to larger prospective clinical
studies.
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